alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 66 studies in Brain scans and imaging published 2021 (page 2 of 3) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of these 66 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

What “Brain scans and imaging” covers

Brain scans and imaging — MRI, PET and other scans: what they show, how early, and how reliably.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Brain : a journal of neurology 2021-02-12

Subjects without amyloid, including three with pathologically confirmed corticobasal degeneration, showed greater regional 18F-AV-1451 retention and associated regional atrophy in areas commonly associated with corticobasal degeneration pathology than healthy control subjects [retention was higher compared to healthy controls (P = 0.0011), driven especially by the precentral gyrus (P = 0.011) and pallidum (P < 0.0001), and greater atrophy was seen in subjects compared to control subjects (P = 0.0004)]. 3 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source

Susceptibility-weighted Imaging: Technical Essentials and Clinical Neurologic Applications

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Radiology 2021-02-23

Susceptibility-weighted imaging (SWI) evolved from simple two-dimensional T2*-weighted sequences to three-dimensional sequences with improved spatial resolution and enhanced susceptibility contrast. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Binding characteristics of [18F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2021-05-27

The novel tau-PET tracer [18F]PI-2620 detects the 3/4-repeat-(R)-tauopathy Alzheimer's disease (AD) and the 4R-tauopathies corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). 2 key findings →

Participants: 29 Evidence: low

Full summary, score breakdown and related studies → Original source

Affective symptoms and regional cerebral tau burden in early-stage Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 48 out of 100. International journal of geriatric psychiatry 2021-03-15

There were significant associations (p < 0.05) between the NPI variables (total score, Affective factor) and entorhinal and precuneus tau across all participants. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source

Altered Cerebellar Resting-State Functional Connectivity in Early-Stage Parkinson's Disease Patients With Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Frontiers in neurology 2021-08-25

Compared to healthy control subjects with no cognitive deficits, altered cerebellar FC were observed in early PD participants with both motor and cognitive deficits, but not in PD patients with normal cognition, nor elderly subjects showing signs of a cognitive impairment. 4 key findings →

Participants: 64 Evidence: low

Full summary, score breakdown and related studies → Original source

The role of multimodal MRI in mild cognitive impairment and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of neuroimaging : official journal of the American Society of Neuroimaging 2021-11-09

Classification of MCI and HC displayed highest accuracy based on diffusion MRI, which besides demonstrated high correlation with clinical scores. 5 key findings →

Participants: 26 Evidence: low

Full summary, score breakdown and related studies → Original source

Evaluation of [18F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Brain communications 2021-08-24

To assess the ability of [18F]PI-2620 to detect regional tau burden in non-Alzheimer's disease tauopathies compared with Alzheimer's disease, patients with progressive supranuclear palsy (n = 3), corticobasal syndrome (n = 2), corticobasal degeneration (n = 1) or Alzheimer's disease (n = 8), and healthy controls (n = 7) were recruited. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Automated production of [18F]Flortaucipir for PET imaging of tauopathies

✓ Peer-reviewed alzhub usefulness score 45 out of 100. American journal of nuclear medicine and molecular imaging 2021-06-15

Radiotracer [18F]Flortaucipir is an FDA-approved diagnostic agent for PET imaging of density and distribution of abnormal tau protein deposition (tauopathies) in Alzheimer's disease. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Locus coeruleus integrity is related to tau burden and memory loss in autosomal-dominant Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neurobiology of aging 2021-12-07

Abnormally phosphorylated tau, an indicator of Alzheimer's disease, accumulates in the first decades of life in the locus coeruleus (LC), the brain's main noradrenaline supply. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Pharmaceuticals (Basel, Switzerland) 2021-01-30

Tauvid has been approved by the U.S. Food and Drug Administration (FDA) in 2020 for positron emission tomography (PET) imaging of adult patients with cognitive impairments undergoing evaluation for Alzheimer's disease (AD) based on tau pathology. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

The Role of 18F-Flortaucipir (AV-1451) in the Diagnosis of Neurodegenerative Disorders

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Cureus 2021-07-26

Tau protein plays a vital role in maintaining the structural and functional integrity of the nervous system; however, hyperphosphorylation or abnormal phosphorylation of tau protein plays an essential role in the pathogenesis of several neurodegenerative disorders. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Bilingualism's Effects on Resting-State Functional Connectivity in Mild Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Brain connectivity 2021-01-21

We found no significant differences between the groups in age, sex, education, or cognitive level, but bilinguals showed higher FC than monolinguals between the posterior part of the superior temporal gyrus and the precuneus, positively correlated with Mini-Mental State Examination scores, and higher fALFF in the thalamus bilaterally. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Functional Brain Connectivity Patterns Associated with Visual Hallucinations in Dementia with Lewy Bodies

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Alzheimer's disease reports 2021-04-29

Seed-based analyses reported decreased connectivity of the lateral geniculate nucleus, the superior parietal lobule and the putamen with the medial frontal gyrus in DLB patients with VH. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed